Last reviewed · How we verify
NCT06608420: Precis-mel 1
Precision Medicine for L/GCMN and Melanoma 1
trial testing Gradient Boosting Survival Analysis (GBSA), in Melanoma (Skin Cancer) in 6,000 participants. Currently enrolling.
1 March 2026
Quick facts
| Lead sponsor | Fundacion Clinic per a la Recerca Biomédica |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 6,000 |
| Start date | 1 March 2024 |
| Primary completion | 1 March 2026 |
| Estimated completion | 30 November 2026 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Gradient Boosting Survival Analysis (GBSA),
- Concordance index
Conditions studied
- Melanoma (Skin Cancer) — all drugs for Melanoma (Skin Cancer) →
- Nevi and Melanomas — all drugs for Nevi and Melanomas →
Sponsor
Fundacion Clinic per a la Recerca Biomédica
Who can join
Eligibility, any sex, with Melanoma (Skin Cancer) or Nevi and Melanomas. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to create a highly multidimensional and multicentric database for melanoma that encompasses cohorts of children, adolescent and young adults. This database will be used to perform survival analysis and evaluate sentinel lymph node (SLNB) positivity in CAYA. The secondary objectives to be met are the following: * Adaptation and optimization of algorithms: work on optimizing existing precision medicine algorithms, which are currently being used in adult patient care, for their application within pediatric and young adult populations. * Implementation of transfer learning: given the limitations associated with pediatric and young adult data, the investigators intend to utilize transfer learning techniques. The study will employ a sequential waterfall methodology, whereby machine learning models trained on adult patient data will be fine-tuned using the more limited data from younger cohorts. * Integration of expert medical opinion: to integrate physician's scientific domain knowledge into the decision support system. This will be facilitated through the comprehensive examination of existing literature, as well as the evaluation of variable risk contributions within each patient group. * AI-based prognostic models: to develop artificial intelligence-based models for the quantitative prognosis of melanoma across the three age groups: adults, young adults, and children.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06608420
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Melanoma (Skin Cancer)
Currently open trials in the same condition.
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07287917 — Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07349303 — Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma · Phase 2 · recruiting
- NCT07376707 — A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic S · Phase 1 · recruiting
Other Fundacion Clinic per a la Recerca Biomédica trials
Trials by the same sponsor.
- NCT07454096 — Application of Radiomics for Diagnosis and Follow-up of Cardiovascular Device Infections: PREDICT Study · Phase 4 · not yet recruiting
- NCT07412873 — Study on Sexual Health and Self-perceived Quality of Life (PROMs) in Patients Treated for Cervical Cancer · Phase 4 · not yet recruiting
- NCT07163403 — First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptid · Phase 1 · recruiting
- NCT07105384 — Quantification Tools for a Novel Tau PET Marker in a Rare Neurological Disease: 18F-PI-2620 in Progressive Supranuclear · Phase 2 · active not recruiting
- NCT06896617 — Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET) · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06608420 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundacion Clinic per a la Recerca Biomédica
- Last refreshed: 28 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06608420.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing